CLARK IAN T

Director Clark sold 264.8K shares (entire holding) at blended $29.73, generating $7.9M; exits to zero post-transaction

Ian T Clark, a director at Olema Pharmaceuticals, executed 3 separate sales on 2025-12-19 totaling 264,800 shares for $7,873,109.28, representing a complete liquidation of his shareholding (pre-transaction: 264,800 shares; post-transaction: 0 shares). The blended average price of $29.73 compares to a current price of $27.67, positioning the sales above the present market level. Olema is trading at -22.8% from its 52-week high of $35.83 and the company reported negative net income of $-42,217,000.00 over its most recent full fiscal year. The complete elimination of his equity stake—coupled with the company's unprofitability and the director's prior track record of 3 open-market sales across all tickers—represents a material change in insider positioning and warrant deeper examination into the context and timing of this comprehensive exit.

Director Ian T. Clark sold 28,611 shares of GH for $3,066,817.23, reducing stake by 74.4% to 9,851 shares

Director Ian T. Clark executed 3 separate sales totaling 28,611 shares on 2025-12-05 at prices ranging from $106.67 to $108.05 (blended average $107.19), generating $3,066,817.23 and reducing his holdings by 74.4% from 38,462 to 9,851 shares. The transaction occurs in the context of a company that has grown revenue 31.0% year-over-year to $265,196,000.00 in the latest quarter but remains unprofitable with negative net income of $-92,725,000.00 over its most recent full fiscal year. The current stock price of $104.17 is 6.4% below the 52-week high of $111.25, and the stock has appreciated 7.7% over the past 30 days and 75.2% over 90 days, placing the sale in an environment of strong recent momentum. The substantial reduction in director holdings warrants observation of whether this reflects a broader shift in insider positioning at the company.